Surf Therapeutics has launched an early feasibility study (EFS) to evaluate its investigational ultrasound neuromodulation device in patients with rheumatoid arthritis (RA), testing whether non-invasive vagus nerve stimulation can modulate immune responses without drugs, implants, or surgery. The SUSTAIN™ platform, based on Surf’s proprietary broad beam acoustic energy delivery, targets immune-related neural pathways with the aim of delivering durable anti-inflammatory benefits.
Why this could mark a turning point for neuromodulation strategies in systemic autoimmune diseases
While neuromodulation has seen regulatory traction in localized indications such as epilepsy and depression, attempts to extend its relevance into systemic immune conditions like rheumatoid arthritis have largely been gated by either invasiveness or inconsistent response. Surf Therapeutics’ platform bypasses those limitations by avoiding implants altogether. Instead, it uses broad beam ultrasound to engage autonomic nerves linked to the cholinergic anti-inflammatory pathway—specifically those associated with vagal tone.
This design is not merely a convenience upgrade. It targets the core issue with biologics and oral immunomodulators: sustained systemic inflammation that often rebounds, demands chronic dosing, and is accompanied by safety trade-offs. If Surf’s approach can trigger immune balance via periodic, at-home stimulation without introducing new pharmacokinetic risks, it could represent a new modality altogether in RA management.
Importantly, the company has committed to a trial format that adheres to rising regulatory standards for device-driven immune modulation: not just an open-label demonstration of effect, but a randomized, sham-controlled structure with measurable endpoints. This positions Surf’s data for future scrutiny by both the U.S. Food and Drug Administration and potential reimbursement bodies seeking reproducibility and cost-value logic.
What sets Surf’s approach apart from prior neuroimmune device interventions
Most neuromodulation therapies in autoimmune conditions have required surgical implantation of stimulation leads—an inherently high-barrier option for a chronic condition like RA, especially in older patients. The standard-bearer in this class, SetPoint Medical, has advanced implantable vagus nerve stimulation devices for inflammatory diseases such as Crohn’s and RA, but adoption has remained niche due to procedural invasiveness, patient acceptance hurdles, and hardware management issues.
Surf’s differentiation lies in its use of broad beam ultrasound rather than electrical stimulation. This allows for deeper tissue penetration and less risk of discomfort or nerve damage. Instead of relying on precise lead placement, the acoustic wavefront can non-specifically stimulate a nerve-rich region—potentially enabling a more flexible treatment regimen that suits home use.
If Surf can demonstrate that its ultrasound platform triggers a systemic immunomodulatory effect similar to implantable VNS systems, but without the surgical complexity, it may be better positioned for mass adoption across rheumatology, dermatology, and other autoimmune subspecialties.
What’s new and what’s still unproven in the current trial setup
The early feasibility study launched by Surf will enroll 40 patients in two stages: an open-label pilot of 10 individuals to establish initial safety and signal detection, followed by a randomized, double-blinded, sham-controlled cohort of 30 participants. This is a deliberate escalation pathway designed to de-risk both safety and placebo confounding—critical in a field where patient-reported outcomes and flare variability are high.
While the clinicaltrials.gov listing (NCT07293871) indicates that the trial is primarily evaluating feasibility and biomarker changes, regulatory observers will be watching for how Surf structures its secondary outcomes. Does it capture DAS28 or ACR50 endpoints? Are inflammatory cytokines such as TNF-α, IL-1β, and IL-6 part of the monitoring panel? Will there be imaging or joint-specific assessment?
Also unresolved is the treatment frequency and duration. Industry watchers suggest that for any neuromodulatory intervention to compete with biologics, it must either offer similar durability per administration or be feasible enough for high-frequency, at-home usage. Without these data, it’s too early to judge how scalable or burdensome the therapy will be in real-world use.
Why RA may be the commercial and clinical wedge for broader neuromodulation adoption
Surf’s strategic focus on RA reflects both the commercial gravity of the disease and the unmet needs in its current management. Despite the widespread use of methotrexate, TNF inhibitors, and JAK inhibitors, over 30% of RA patients report inadequate control or intolerable side effects. Furthermore, long-term biologic use is associated with heightened infection risk, liver enzyme abnormalities, and rising payer scrutiny.
Given RA’s substantial disease burden and the frequency of flares, a safe, non-drug, non-surgical option that patients can self-administer may prove attractive across multiple dimensions: clinician enthusiasm, payer interest, and patient adherence. It may also find a niche as an add-on for patients already on immunomodulatory therapy, but seeking flare suppression without dosage escalation.
If successful, Surf’s platform could be extended to other chronic inflammatory diseases with neural-immune cross-talk implications, including psoriasis, inflammatory bowel disease, and even long COVID—a field where vagus nerve dysfunction is increasingly implicated.
What the new board appointments signal about Surf’s next strategic phase
The simultaneous announcement of new board members with device commercialisation and regulatory strategy credentials is no accident. Jason Witherington, formerly of Galvani Bioelectronics and Johnson & Johnson, brings deep insight into translational medicine frameworks in inflammatory disorders. His presence may help Surf navigate the transition from exploratory trial design to pivotal trials with defined endpoints.
Perhaps even more telling is the addition of Shri Raghunathan, the founder of Noctrix Health, who previously led the development of a successful non-invasive neuromodulation product for Restless Legs Syndrome. Raghunathan’s experience in scaling devices for at-home use, securing reimbursement, and navigating FDA pathways for non-drug interventions will be critical as Surf looks beyond proof-of-concept into broader adoption planning.
Both appointments suggest that Surf sees itself not just as a biotech experimenting with a novel approach, but as a commercial-stage company preparing to stake a claim in the emerging field of drug-free immune modulation.
Why reimbursement, training, and long-term data may become gating factors
Despite its promise, the neuromodulation space is littered with well-validated devices that never gained commercial traction due to reimbursement bottlenecks, unclear user training protocols, and challenges in demonstrating consistent long-term outcomes.
Even if Surf’s trial meets its primary safety and biomarker goals, payers may ask: how does this intervention compare with a biosimilar TNF inhibitor in cost per remission? What is the expected duration of effect? How is adherence monitored? Without a clear framework for physician onboarding and treatment titration, adoption may lag even with a positive clinical profile.
To mitigate this, Surf will likely need to invest early in real-world evidence collection, integration with digital monitoring tools, and patient-reported outcome platforms that can be fed into regulatory and HTA dossiers. The company may also need to pursue payer partnership models that allow for outcomes-based payment structures—a route increasingly common in device–drug hybrid categories.
Will Surf’s SUSTAIN platform bring at-home neuromodulation to mainstream rheumatology? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →